News briefing: Regeneron/Sanofi post positive PhIII Dupixent data in pediatric asthma; Vineti scores $33M Series C extension
Regeneron and Sanofi revealed positive Phase III data for their blockbuster Dupixent on Tuesday, paving a potential path forward in pediatric asthma.
Dupixent, evaluated in children between ages 6 and 11, met its primary endpoint of lowering the rate of severe asthma attacks in two patient populations by 65% and 59% per year compared to placebo. The drug also showed improved lung function by 10.15 and 10.53 percentage points over baseline, compared to 4.83 and 5.32 percentage points for placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.